Literature DB >> 21596749

Anti-heparan sulfate peptides that block herpes simplex virus infection in vivo.

Vaibhav Tiwari1, Jian Liu, Tibor Valyi-Nagy, Deepak Shukla.   

Abstract

Heparan sulfate (HS) and its highly modified form, 3-O-sulfated heparan sulfate (3-OS HS), contribute strongly to herpes simplex virus type-1 (HSV-1) infection in vitro. Here we report results from a random M13-phage display library screening to isolate 12-mer peptides that bind specifically to HS, 3-OS HS, and block HSV-1 entry. The screening identified representative candidates from two-different groups of anti-HS peptides with high positive charge densities. Group 1, represented by G1 peptide (LRSRTKIIRIRH), belongs to a class with alternating charges (XRXRXKXXRXRX), and group 2, represented by G2 peptide (MPRRRRIRRRQK), shows repetitive charges (XXRRRRXRRRXK). Viral entry and glycoprotein D binding assays together with fluorescent microscopy data indicated that both G1 and G2 were potent in blocking HSV-1 entry into primary cultures of human corneal fibroblasts and CHO-K1 cells transiently expressing different glycoprotein D receptors. Interestingly, G2 peptide isolated against 3-OS HS displayed wider ability to inhibit entry of clinically relevant strains of HSV-1 and some divergent members of herpesvirus family including cytomegalovirus and human herpesvirus-8. To identify functional residues within G1 and G2, we performed point mutations and alanine-scanning mutagenesis. Several arginine and a lysine residues were needed for anti-HSV-1 activity, suggesting the importance of the positively charged residues in virus-cell binding and virus-induced membrane fusion. In vivo administration of G1 or G2 peptide as a prophylactic eye drop completely blocked HSV-1 spread in the mouse cornea as evident by immunohistochemistry. This result also highlights an in vivo significance of HS and 3-OS HS during ocular herpes infection.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21596749      PMCID: PMC3137111          DOI: 10.1074/jbc.M110.201103

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

Review 1.  Molecular diversity of heparan sulfate.

Authors:  J D Esko; U Lindahl
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

2.  Identification of a dendrimeric heparan sulfate-binding peptide that inhibits infectivity of genital types of human papillomaviruses.

Authors:  Manuela Donalisio; Marco Rusnati; Andrea Civra; Antonella Bugatti; Donatella Allemand; Giovanna Pirri; Andrea Giuliani; Santo Landolfo; David Lembo
Journal:  Antimicrob Agents Chemother       Date:  2010-07-19       Impact factor: 5.191

3.  Activation of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) lytic replication by human cytomegalovirus.

Authors:  J Vieira; P O'Hearn; L Kimball; B Chandran; L Corey
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

4.  Cell fusion induced by herpes simplex virus glycoproteins gB, gD, and gH-gL requires a gD receptor but not necessarily heparan sulfate.

Authors:  P E Pertel; A Fridberg; M L Parish; P G Spear
Journal:  Virology       Date:  2001-01-05       Impact factor: 3.616

5.  Heparin sulphate D-glucosaminyl 3-O-sulfotransferase 3B1 plays a role in HBV replication.

Authors:  Zhenzhen Zhang; Xiang Liu; Juan Chen; Huaibin Su; Qiang Luo; Jia Ye; Ni Tang; Wenlu Zhang; WeiXian Chen; Ben C B Ko; Ailong Huang
Journal:  Virology       Date:  2010-08-11       Impact factor: 3.616

Review 6.  Herpes simplex virus epidemiology and ocular importance.

Authors:  T J Liesegang
Journal:  Cornea       Date:  2001-01       Impact factor: 2.651

7.  Expanding the role of 3-O sulfated heparan sulfate in herpes simplex virus type-1 entry.

Authors:  Christopher D O'Donnell; Maria Kovacs; Jihan Akhtar; Tibor Valyi-Nagy; Deepak Shukla
Journal:  Virology       Date:  2009-12-11       Impact factor: 3.616

8.  Peptide-derivatized dendrimers inhibit human cytomegalovirus infection by blocking virus binding to cell surface heparan sulfate.

Authors:  Anna Luganini; Andrea Giuliani; Giovanna Pirri; Lorena Pizzuto; Santo Landolfo; Giorgio Gribaudo
Journal:  Antiviral Res       Date:  2010-01-18       Impact factor: 5.970

Review 9.  Viral entry mechanisms: cellular and viral mediators of herpes simplex virus entry.

Authors:  Jihan Akhtar; Deepak Shukla
Journal:  FEBS J       Date:  2009-12       Impact factor: 5.542

10.  Spermatozoa capture HIV-1 through heparan sulfate and efficiently transmit the virus to dendritic cells.

Authors:  Ana Ceballos; Federico Remes Lenicov; Juan Sabatté; Christian Rodríguez Rodrígues; Mercedes Cabrini; Carolina Jancic; Silvina Raiden; Mónica Donaldson; Rodolfo Agustín Pasqualini; Clara Marin-Briggiler; Mónica Vazquez-Levin; Francisco Capani; Sebastián Amigorena; Jorge Geffner
Journal:  J Exp Med       Date:  2009-10-26       Impact factor: 14.307

View more
  52 in total

Review 1.  Role of heparan sulfate in sexually transmitted infections.

Authors:  Vaibhav Tiwari; Erika Maus; Ira M Sigar; Kyle H Ramsey; Deepak Shukla
Journal:  Glycobiology       Date:  2012-07-06       Impact factor: 4.313

Review 2.  Role of heparan sulfate in ocular diseases.

Authors:  Paul J Park; Deepak Shukla
Journal:  Exp Eye Res       Date:  2013-02-11       Impact factor: 3.467

Review 3.  Peptide therapeutics for treating ocular surface infections.

Authors:  Curtis R Brandt
Journal:  J Ocul Pharmacol Ther       Date:  2014-09-24       Impact factor: 2.671

Review 4.  Pathological processes activated by herpes simplex virus-1 (HSV-1) infection in the cornea.

Authors:  Lulia Koujah; Rahul K Suryawanshi; Deepak Shukla
Journal:  Cell Mol Life Sci       Date:  2018-10-16       Impact factor: 9.261

5.  Enterovirus 71 uses cell surface heparan sulfate glycosaminoglycan as an attachment receptor.

Authors:  Chee Wah Tan; Chit Laa Poh; I-Ching Sam; Yoke Fun Chan
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

Review 6.  Glycoprotein targeted therapeutics: a new era of anti-herpes simplex virus-1 therapeutics.

Authors:  Thessicar E Antoine; Paul J Park; Deepak Shukla
Journal:  Rev Med Virol       Date:  2013-02-26       Impact factor: 6.989

7.  Susceptibility of human iris stromal cells to herpes simplex virus 1 entry.

Authors:  John Baldwin; Paul J Park; Brian Zanotti; Erika Maus; Michael V Volin; Deepak Shukla; Vaibhav Tiwari
Journal:  J Virol       Date:  2013-01-23       Impact factor: 5.103

8.  Cell entry mechanisms of HSV: what we have learned in recent years.

Authors:  Alex M Agelidis; Deepak Shukla
Journal:  Future Virol       Date:  2015-10-01       Impact factor: 1.831

9.  The D-form of a novel heparan binding peptide decreases cytomegalovirus infection in vivo and in vitro.

Authors:  Elisabeth A Pitt; Pranay Dogra; Ravi S Patel; Angela Williams; Jonathan S Wall; Tim E Sparer
Journal:  Antiviral Res       Date:  2016-09-25       Impact factor: 5.970

10.  An investigative peptide-acyclovir combination to control herpes simplex virus type 1 ocular infection.

Authors:  Paul J Park; Thessicar E Antoine; Asim V Farooq; Tibor Valyi-Nagy; Deepak Shukla
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-09-27       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.